Browse studies

Find your next paid study

136 recruiting studies matching your filters

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH a…

Pulmonary Arterial HypertensionIdiopathic Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Bastiaan DriehuysNCT06104228

Phase 3

Comparing Treatment With Versus Without Neoadjuvant Doxorubicin and Ifosfamide in Selected Patients With High-Risk Resectable Soft-Tissue Sarcoma

This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrol…

Resectable LiposarcomaResectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic Sarcoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer CenterNCT07823491

Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry

The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to…

Soft Tissue Lesion

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Galvanize Therapeutics, Inc.NCT05851430

Phase 3

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. …

Alveolar Soft Part SarcomaLeiomyosarcomaSynovial Sarcoma+1 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Advenchen Laboratories, LLCNCT03016819

Phase 1

EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a

MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The stu…

Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Medigene AGNCT06748872

Observational

Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns

This investigation will be a randomized, prospective, longitudinal clinical trial to study the clinical performance of a new monolithic, zirconia material with…

Dental Disorders Hard Tissues of TeethDental Diseases

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Ivoclar Vivadent AGNCT06173167

Phase 1

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor mic…

Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Pure Biologics S.A.NCT06700070

Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells gene…

Pediatric Solid TumorOsteosarcomaRhabdomyosarcoma+13 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT04897321

Observational

Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital

This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James C…

Breast CarcinomaMalignant Digestive System NeoplasmMalignant Female Reproductive System Neoplasm+9 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer Center

Phase 4

Randomized Prospective Evaluation of Ovine Forestomach Matrix (OFM) and NPWT to Accelerate Tissue Coverage Over Exposed Structures

Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone

Soft Tissue DefectsSoft Tissue WoundsTraumatic Soft Tissue Defect

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Aroa Biosurgery LimitedNCT07385313

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is parti…

Neoplasms, Connective and Soft TissueBone Neoplasms

Estimated

~$10 – $750

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer CenterNCT02677961

Phase 1

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.